国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2011年
6期
498-501
,共4页
崔晋荣%王兆宏%薛亚军%王振业%杜寿龙
崔晉榮%王兆宏%薛亞軍%王振業%杜壽龍
최진영%왕조굉%설아군%왕진업%두수룡
复方蒌薤合剂%血管反应性%NO%ET-1%NOS
複方蔞薤閤劑%血管反應性%NO%ET-1%NOS
복방루해합제%혈관반응성%NO%ET-1%NOS
Louxie mixture%Vascular reactivity%Nitric oxide%Endothelin-1%Nitric oxide syntheses
目的 探讨瓜蒌薤白类方(自拟复方蒌薤合剂)对实验性动脉粥样硬化(atherosclerosis,AS) 大鼠血管反应的影响.方法 采用高脂饲料喂养Wister 大鼠制备动脉粥样硬化模型.大鼠按体重进行随机区组设计,分为4 组各10 只,正常对照组(A 组)、高脂模型组(B 组)、高脂阿托伐他汀治疗组(C 组,灌服阿托伐他汀10 mg/kg·d-1,qd)和高脂复方蒌薤合剂治疗组(D 组,灌服复方蒌薤合剂bid),共饲养干预10 周.①在0 周和10 周末取大鼠血浆,测定内皮素(ET-1 )、一氧化氮(NO)和一氧化氮合酶(NOS); ②10 周末取大鼠胸主动脉制备血管环,测定血管环对不同浓度乙酰胆碱(Ach)及硝普钠(SNP)的舒张反应性,以量-效曲线、最大舒张反应(Emax )及引起最大舒张反应一半时的药物浓度(IC50)表示血管反应性.结果 ① B 组0 周与10 周时血浆NO、NOS 水平明显降低[NO 0 周时为(35.73±3.72)μmol/L,10 周时为(19.03±1.72)μmol/L;NOS 0 周时为(24.78±0.25)U/ml,10 周时为(15.36±0.24)U/ml,P 均＜0.01];ET-1 水平明显上升[0 周时为(34.58±4.00)pg/ml,10 周时为(117.58±5.34)pg/ml,P＜0.01].阿托伐他汀和复方蒌薤合剂均可提高血浆NO 和NOS 水平[NO C 组:(31.30±1.96)μmol/L;D 组:(32.85± 3.70)μmol/L),P＜0.01];[NOS C 组:(21.96±1.07)U/ml;D 组:(19.78±1.20)U/ml,P＜0.01]; 降低ET-1 水平[C 组:(58.26±5.14)pg/ml;D 组:(59.30±5.73)pg/ml,P＜0.01];②各组大鼠对SNP 诱导的非内皮依赖性舒张反应差异无统计学意义[EmaxA 组:(97.33±1.31)%;B 组:(98.24±1.04)%; C 组:(97.52±1.09)%;D 组:(97.91±1.59)%,P 均＞0.05];对Ach 诱导的内皮依赖性舒张反应差异有统计学意义[EmaxA 组:(72.65±3.31)%;B 组:(32.68±2.39)%;C 组:(61.63±2.07)%;D 组:(57.58± 2.43)%,P 均＜0.01],B 组较A 组量效曲线非平行左移,C 组、D 组较B 组可使量效曲线非平行右移,C、D 两组组间比较差异无统计学意义[Emax C 组:(61.63±2.07)%;D 组:(57.58±2.43)%,P＞0.05].结论 中药复方蒌薤合剂对动脉粥样硬化后血管舒张功能下降有保护作用.
目的 探討瓜蔞薤白類方(自擬複方蔞薤閤劑)對實驗性動脈粥樣硬化(atherosclerosis,AS) 大鼠血管反應的影響.方法 採用高脂飼料餵養Wister 大鼠製備動脈粥樣硬化模型.大鼠按體重進行隨機區組設計,分為4 組各10 隻,正常對照組(A 組)、高脂模型組(B 組)、高脂阿託伐他汀治療組(C 組,灌服阿託伐他汀10 mg/kg·d-1,qd)和高脂複方蔞薤閤劑治療組(D 組,灌服複方蔞薤閤劑bid),共飼養榦預10 週.①在0 週和10 週末取大鼠血漿,測定內皮素(ET-1 )、一氧化氮(NO)和一氧化氮閤酶(NOS); ②10 週末取大鼠胸主動脈製備血管環,測定血管環對不同濃度乙酰膽堿(Ach)及硝普鈉(SNP)的舒張反應性,以量-效麯線、最大舒張反應(Emax )及引起最大舒張反應一半時的藥物濃度(IC50)錶示血管反應性.結果 ① B 組0 週與10 週時血漿NO、NOS 水平明顯降低[NO 0 週時為(35.73±3.72)μmol/L,10 週時為(19.03±1.72)μmol/L;NOS 0 週時為(24.78±0.25)U/ml,10 週時為(15.36±0.24)U/ml,P 均＜0.01];ET-1 水平明顯上升[0 週時為(34.58±4.00)pg/ml,10 週時為(117.58±5.34)pg/ml,P＜0.01].阿託伐他汀和複方蔞薤閤劑均可提高血漿NO 和NOS 水平[NO C 組:(31.30±1.96)μmol/L;D 組:(32.85± 3.70)μmol/L),P＜0.01];[NOS C 組:(21.96±1.07)U/ml;D 組:(19.78±1.20)U/ml,P＜0.01]; 降低ET-1 水平[C 組:(58.26±5.14)pg/ml;D 組:(59.30±5.73)pg/ml,P＜0.01];②各組大鼠對SNP 誘導的非內皮依賴性舒張反應差異無統計學意義[EmaxA 組:(97.33±1.31)%;B 組:(98.24±1.04)%; C 組:(97.52±1.09)%;D 組:(97.91±1.59)%,P 均＞0.05];對Ach 誘導的內皮依賴性舒張反應差異有統計學意義[EmaxA 組:(72.65±3.31)%;B 組:(32.68±2.39)%;C 組:(61.63±2.07)%;D 組:(57.58± 2.43)%,P 均＜0.01],B 組較A 組量效麯線非平行左移,C 組、D 組較B 組可使量效麯線非平行右移,C、D 兩組組間比較差異無統計學意義[Emax C 組:(61.63±2.07)%;D 組:(57.58±2.43)%,P＞0.05].結論 中藥複方蔞薤閤劑對動脈粥樣硬化後血管舒張功能下降有保護作用.
목적 탐토과루해백류방(자의복방루해합제)대실험성동맥죽양경화(atherosclerosis,AS) 대서혈관반응적영향.방법 채용고지사료위양Wister 대서제비동맥죽양경화모형.대서안체중진행수궤구조설계,분위4 조각10 지,정상대조조(A 조)、고지모형조(B 조)、고지아탁벌타정치료조(C 조,관복아탁벌타정10 mg/kg·d-1,qd)화고지복방루해합제치료조(D 조,관복복방루해합제bid),공사양간예10 주.①재0 주화10 주말취대서혈장,측정내피소(ET-1 )、일양화담(NO)화일양화담합매(NOS); ②10 주말취대서흉주동맥제비혈관배,측정혈관배대불동농도을선담감(Ach)급초보납(SNP)적서장반응성,이량-효곡선、최대서장반응(Emax )급인기최대서장반응일반시적약물농도(IC50)표시혈관반응성.결과 ① B 조0 주여10 주시혈장NO、NOS 수평명현강저[NO 0 주시위(35.73±3.72)μmol/L,10 주시위(19.03±1.72)μmol/L;NOS 0 주시위(24.78±0.25)U/ml,10 주시위(15.36±0.24)U/ml,P 균＜0.01];ET-1 수평명현상승[0 주시위(34.58±4.00)pg/ml,10 주시위(117.58±5.34)pg/ml,P＜0.01].아탁벌타정화복방루해합제균가제고혈장NO 화NOS 수평[NO C 조:(31.30±1.96)μmol/L;D 조:(32.85± 3.70)μmol/L),P＜0.01];[NOS C 조:(21.96±1.07)U/ml;D 조:(19.78±1.20)U/ml,P＜0.01]; 강저ET-1 수평[C 조:(58.26±5.14)pg/ml;D 조:(59.30±5.73)pg/ml,P＜0.01];②각조대서대SNP 유도적비내피의뢰성서장반응차이무통계학의의[EmaxA 조:(97.33±1.31)%;B 조:(98.24±1.04)%; C 조:(97.52±1.09)%;D 조:(97.91±1.59)%,P 균＞0.05];대Ach 유도적내피의뢰성서장반응차이유통계학의의[EmaxA 조:(72.65±3.31)%;B 조:(32.68±2.39)%;C 조:(61.63±2.07)%;D 조:(57.58± 2.43)%,P 균＜0.01],B 조교A 조량효곡선비평행좌이,C 조、D 조교B 조가사량효곡선비평행우이,C、D 량조조간비교차이무통계학의의[Emax C 조:(61.63±2.07)%;D 조:(57.58±2.43)%,P＞0.05].결론 중약복방루해합제대동맥죽양경화후혈관서장공능하강유보호작용.
Objective To investigate the effect of Chinese medicine Louxie mixture on vascular reactivity in atherosclerosis rats. Methods Forty male rats were randomly divided into four groups: the control group (A group, n＝10) was fed with normal diet; the model group (B group, n＝10), atorvastatin treated group (C group, n＝10 and Louxie mixture group (D group, n＝10) were fed with high fat/cholesterol diet. Atorvastatin 10 mg/kg·d-1 was administered to C group and Louxie mixture to D group for 10 weeks by gavages. Serum endothelin-1 (ET-1), nitric oxide (NO) and nitric oxide syntheses (NOS) were observed in different groups before and after the treatment. Vascular reactivity of aortic rings was measured by both the sodium nitroprusside(SNP)-induced endothelium-independent relaxation (NEDR) and the acetylcholine (Ach)-induced endothelium-dependent relaxation (EDR) in different groups. Results After treatment, the (19.03±1.72)μmol/l; NOS (24.78±0.25)U/ml vs (15.36±0.24U/ml), P＜0.01], while the level of ET-1in B levels of NO and NOS in B group were significantly lower than those in A group [NO(35.73±3.72)μmol/l vs group was higher than that in A group [(34.58±4.00) pg/ml vs (117.58±5.34)pg/ml,P＜0.01]. The levels of NO and NOS were significantly increased and the level of ET-1 was decreased in C and D groups after the treatment [NO(C: 31.30±1.96 umol/l;D: 32.85±3.70 umol/l); NOS (C: 21.96±1.07 U/ml ; D: 19.78± 1.20U/ml ); ET (C:58.26±5.14 pg/ml; D:59.30±5.73 pg/ml), P＜0.01]. The activities of NEDR were similar in four groups[SNP Emax (A: 97.33±1.31; B: 98.24±1.04;C: 97.52±1.09; D: 97.91±1.59)%, P＞0.05], but the level of EDR in the B group (P＜0.01) was the lowest among four groups [Ach Emax (A: 72.65±3.31; B: 32.68±2.39;C: 61.63±2.07; D: 57.58±2.43)%, P＜0.01]. Conclusion Chinese medicine Louxie mixture can protect vascular function in atherosclerosis rats.
